Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Irina Konstantinovsky net worth and biography

Irina Konstantinovsky Biography and Net Worth

EVP of Horizon Therapeutics Public

Irina Konstantinovsky joined Horizon in 2017. Before joining Horizon, she was vice president of global talent at Baxter International Inc. where she led a team of talent professionals worldwide and oversaw organizational effectiveness, leadership development, inclusion and diversity and talent acquisition. She and her team were responsible for talent management strategies, programs and systems for more than 50,000 employees worldwide.

Before Baxter, Konstantinovsky spent 15 years in senior partner and director roles at Towers Watson (currently Willis Towers Watson), a global human resources consulting firm serving Fortune 1000 companies. While in these roles, she served as the interim chief human resource officer at Capital BlueCross for two years.

Konstantinovsky has a Bachelor of Arts in education from the University of Buenos Aires and master's degrees in higher education and industrial and labor relations from Cornell University. In addition, she currently serves as the Chair of the Board of Directors for the Human Resource Management Association of Chicago and is also on the YWCA of Metropolitan Chicago board.

What is Irina Konstantinovsky's net worth?: The estimated net worth of Irina Konstantinovsky is at least $13.11 million as of January 6th, 2021. Ms. Konstantinovsky owns 112,717 shares of Horizon Therapeutics Public stock worth more than $13,108,987 as of December 18th. This net worth approximation does not reflect any other assets that Ms. Konstantinovsky may own. Learn More about Irina Konstantinovsky's net worth.
How do I contact Irina Konstantinovsky?: The corporate mailing address for Ms. Konstantinovsky and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Irina Konstantinovsky's contact information.
Has Irina Konstantinovsky been buying or selling shares of Horizon Therapeutics Public?: Irina Konstantinovsky has not been actively trading shares of Horizon Therapeutics Public within the last three months. Most recently, Irina Konstantinovsky sold 26,844 shares of the business's stock in a transaction on Wednesday, January 6th. The shares were sold at an average price of $74.76, for a transaction totalling $2,006,857.44. Following the completion of the sale, the executive vice president now directly owns 112,717 shares of the company's stock, valued at $8,426,722.92. Learn More on Irina Konstantinovsky's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Irina Konstantinovsky Insider Trading History at Horizon Therapeutics Public

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/6/2021	Sell	26,844	$74.76	$2,006,857.44	112,717
9/16/2020	Sell	8,919	$78.88	$703,530.72	36,022
4/20/2020	Sell	19,886	$34.13	$678,709.18	35,389
9/12/2019	Sell	17,838	$26.70	$476,274.60	44,819

Irina Konstantinovsky Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03

First JFK… next Elon?

From Porter & Company | Ad